COVID-19: addressing the global health crisis
USP is playing a critical role in the public health response to COVID-19 disease, caused by the virus SARS-CoV-2. USP is helping to accelerate the work of scientists and manufacturers developing vaccines and treatments, supporting front line workers impacted by shortages of critical drugs and personal protection equipment and helping to build a more resilient global medicines supply chain.
Speeding the development of quality vaccines and treatments.
USP is working on developing insights on current supply chain vulnerabilities and looking into ways of strengthening it for the future.
Essential services
Ensuring uninterrupted service for stakeholders and customers during this pandemic.
USP's Ronald Piervincenzi and Mike Ganio from the American Society of Health System Pharmacists, discuss potential shortages of drugs made in China and India, and shipped throughout the world.
Poor-quality medical products erode trust in health systems. Professor Ashish Jha explains why protecting people from substandard and falsified medicines is particularly essential to protect global public health during disease outbreaks, like the coronavirus pandemic
Shortages of quality essential medicines during the COVID-19 pandemic are compromising our ability to save lives. Learn how USP India is responding to drug shortages and protecting public health.
USP is committed to the introduction of recombinant Factor C (rFC) as a synthetic alternative as a way to drive adoption of recombinant reagents as alternatives to naturally sourced reagents.
USP Education is currently providing all on-demand education at a 75% discount, now extended through June 30, 2020.
